Pharmaceutical

Risk adjusted net present value: What is the current valuation of Cullinan Therapeutics’s CLN-619?

CLN-619 is a monoclonal antibody commercialized by Cullinan Therapeutics, with a leading Phase I program in Ovarian Cancer;Cervical Cancer;Endometrial Cancer.

Dec 15, 2024 - 06:00
CLN-619 is a monoclonal antibody commercialized by Cullinan Therapeutics, with a leading Phase I program in Ovarian Cancer;Cervical Cancer;Endometrial Cancer.
Read the original article

Tags:

Previous Article

Risk adjusted net present value: What is the current valuation of IN8bio’s INB-400?

Next Article

Risk adjusted net present value: What is the current valuation of Avidity Biosci...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Carl June unveils a plan for a ‘universal CAR-T’

STAT+: Carl June unveils a plan for a ‘universal CAR-T’

Sep 2, 2023

AstraZeneca’s sBLA for LS-SCLC treatment gains FDA priority review

AstraZeneca’s sBLA for LS-SCLC treatment gains FDA prio...

Aug 17, 2024

Lundbeck acquires all outstanding shares of Longboard Pharma

Lundbeck acquires all outstanding shares of Longboard P...

Dec 5, 2024